Vitiligo

Dr. Raj Chovatiya shares his thoughts on the recent approval of ruxolitinib for treatment of vitiligo and where he might use it, either alone or in combination with other vitiligo treatments.

As 2022 concludes, a dermatologist reflects on the first drug approved for vitiligo.

Iltefat Hamzavi, MD, explores key areas of patient communication that may shape adherence and outcomes in patients with vitiligo.

Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.

Pearl E. Grimes, MD, discusses intervention strategies for vitiligo, including stabilization, repigmentation, and maintenance. She also explores factors that impact therapeutic outcomes.

John E. Harris, MD, PhD, reviews factors that shape prevalence of vitiligo and also explores the impact of vitiligo on patient quality of life.

In a recent study, DAMPs were found to play a major role in deteriorating vitiligo conditions by initiating host defenses against signals of danger.

Why patience is key following the major FDA decision earlier this year.

An interview with Dr. Rosen regarding his SDPA 2022 presentation on dermatologic conditions with white spots that are often misdiagnosed as vitiligo.

A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.

In one of his SDPA 2022 presentations, Dr. Rosen spoke on different dermatological conditions with vitiligo-like presentations.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests the use of simvastatin treatment may be helpful for patients with nonsegmental vitiligo and dyslipidemia.

A new population-based study demonstrates an association between patients having systemic sclerosis and vitiligo, suggesting both conditions may need to be monitored for comorbidities.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

Only 7% of trials included a patient-reported outcome measure as a primary outcome measure.

Evaluating the stigma associated with various dermatologic conditions is more accessible with the validated PUSH-D questionnaire.

New cohort analysis data suggest the risk of COVID-19 death is about 38% decreased among patients with the autoimmune disease.

An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.

A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.

A 1-unit increase in mean weekly SPD scores was linked to a 1.4-times increase in clinic visits for itch among adults aged 65 years or old.

New research demonstrated a correlation between specific VDR polymorphisms and patients’ liability of having vitiligo.

A discussion with Dr. Lal on the topics of benefits of ruxolitinib treatment for nonsegmental vitiligo, as well as on the recent recall of hair products due to benzene risk.

Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.